QLT Inc (QLTI) CEO Buys 15K Shares
More News related to QLTI
- QLT announces interim results of radical study evaluating Visudyne combination therapy
- QLT announces commencement of tender offer
- QLT Inc. (QLTI) Announces $50M Dutch Tender Offer
- QLT to repurchase up to US$ 50 million of common shares - Modified "Dutch Auction" tender offer to commence on or about December 4, 2008
- Beacon Equity Issues Technical Trade Alerts on Market Movers: INCY, QLTI, LINTA, PDGI, FRPT, SVNT
More News related to Insider Trades
- ARGUS Downgrades Smith International (SII) to Hold
- Cantor Fitzgerald Downgrades Audiocodes (AUDC) to Hold After Negative 4Q Preannouncement
- MDB Capital Downgrades Ener1 (HEV) to Sell, Suspends Earnings Model and Valuation on Stock No Longer Justified
- DA Davidson Downgrades Ambassadors Group (EPAX) to Neutral
- SunTrust Downgrades Ruby Tuesday, Inc. (RT) to Neutral
QLT Inc. (Nasdaq: QLTI) CEO Robert L. Butchofsky bought 15,000 shares on 10/30 at $2.42, bringing his stake to 90,497 shares.
QLT, Inc., a biopharmaceutical company, engages in the research and development of pharmaceutical products in the fields of ophthalmology and dermatology.
Related Categories
Insider TradesStocks Mentioned
+0.06Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
